Enjoy complimentary customisation on priority with our Enterprise License!
The intravenous immunoglobulins market size has the potential to grow by USD 6.79 billion during 2020-2024, and the market's growth momentum will accelerate during the forecast period.
This report provides a detailed analysis of the market by therapy area (neurology, immunology, hematology, and others) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market's competitive landscape and offers information on several market vendors, including ADMA Biologics Inc., Baxter International Inc., Bio Products Laboratory Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Octapharma AG, and Takeda Pharmaceutical Co. Ltd.
Browse TOC and LoE with selected illustrations and example pages of Intravenous Immunoglobulins Market
The intravenous immunoglobulins market is fragmented and characterized by the presence of several leading vendors. ADMA Biologics Inc., Baxter International Inc., and Bio Products Laboratory Ltd. are some of the major market participants. Additionally, numerous global as well as local vendors are operating in this market, leading to price-wars as well as high competition for larger market shares.
Market drivers such as the increase in disease prevalence will offer immense growth opportunities. However, factors such as the complex and cost-intensive manufacturing will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market position, this intravenous immunoglobulins market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market's competitive landscape and offers information on the products offered by various companies. Moreover, this intravenous immunoglobulins market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading companies, including:
For more insights on the market share of various regions Request for a FREE sample now!
North America was the largest intravenous immunoglobulins market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The presence of improved treatment regimen, the increased awareness about rare and fatal diseases, technological advances, and the rise in disease prevalence will significantly drive intravenous immunoglobulins market growth in this region over the forecast period.
44% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for intravenous immunoglobulins in North America. However, market growth in this region will be slower than the growth of the market in Asia and Europe.
Request for a FREE sample and Get more information on the market contribution of various segments
The intravenous immunoglobins therapy is the accepted treatment for major bleeding disorders, including immune thrombocytopenia purpura, alloimmune thrombocytopenia, and hemolytic disease in newborns. The increasing incidence of bleeding disorders across the globe and the prophylaxis use in surgeries will be the major factors driving the intravenous immunoglobulins market growth in the hematology segment during the next few years. This report provides an accurate prediction of the contribution of all the segments to the growth of the intravenous immunoglobulins market size.
According to Technavio's market research report, the global intravenous immunoglobulins market will grow at a CAGR of about 10% during the forecast period. The increasing prevalence of various neurological and hematologic disorders will be one of the major factors that will drive the growth of the market during the next four years. It has been observed that in addition to a rise in myasthenia gravis, the recent years also witnessed a growth in the prevalence of other neurological diseases such as Guillain-Barre Syndrome, CIDP, and multifocal motor neuropathy. Additionally, there is a considerable increase in the prevalence of hematic disorders in children. This will subsequently fuel the market's growth since immunoglobulin is considered to be the first line of treatment for such conditions. Also, the growth in the geriatric population, which is more susceptible to diseases due to poor immunity, will demand the need for better immunological treatment that will again fuel the demand for intravenous immunoglobulins.
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.